Mylan Inc. MYL today
announced that its subsidiary Mylan Pharmaceuticals Inc. has received final
approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated
New Drug Application (ANDA) for Quinine Sulfate Capsules USP, 324 mg. This
product is the generic version of Mutual Pharmaceutical Company, Inc.'s
Qualaquin^® Capsules, and is an antimalarial drug indicated only for treatment
of uncomplicated Plasmodium falciparum malaria.(1)
Quinine Sulfate Capsules USP, 324 mg, had U.S. sales of approximately $31.9
million for the 12 months ending Sept. 30, 2012, according to IMS Health.
Mylan has begun shipping this product.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in